The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patientsMPE25 July 2025
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, Myeloma27 June 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
AL amyloidosis phase III clinical trial of birtamimab fails to meet primary endpointAL amyloidosis26 May 2025
